|4Jun 7, 7:28 PM ET

OSI PHARMACEUTICALS INC 4

4 · OSI PHARMACEUTICALS INC · Filed Jun 7, 2010

Insider Transaction Report

Form 4
Period: 2010-06-03
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2010-06-03$57.50/sh6,000$345,0000 total
    Exercise: $30.39Exp: 2013-06-13Common Stock (6,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2010-06-03$57.50/sh10,000$575,0000 total
    Exercise: $38.63Exp: 2015-06-10Common Stock (10,000 underlying)
  • Disposition from Tender

    Common Stock

    2010-06-03$57.50/sh18,136$1,042,82011,750 total
  • Disposition to Issuer

    Common Stock

    2010-06-03$57.50/sh11,000$632,500750 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2010-06-03$57.50/sh25,000$1,437,5000 total
    Exercise: $16.92Exp: 2013-01-01Common Stock (25,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2010-06-03$57.50/sh15,000$862,5000 total
    Exercise: $38.61Exp: 2014-03-16Common Stock (15,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2010-06-03$57.50/sh15,000$862,5000 total
    Exercise: $45.60Exp: 2015-03-15Common Stock (15,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2010-06-03$57.50/sh6,000$345,0000 total
    Exercise: $36.25Exp: 2014-06-12Common Stock (6,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2010-06-03$57.50/sh10,000$575,0000 total
    Exercise: $28.65Exp: 2016-06-16Common Stock (10,000 underlying)
Footnotes (2)
  • [F1]Represents the number of Deferred Stock Units that were canceled in exchange for a cash payment of $57.50 per unit in accordance with the Agreement and Plan of Merger, dated as of May 16, 2010, among OSI Pharmaceuticals, Inc., Astellas Pharma Inc., Astellas US Holding, Inc. and Ruby Acquisition, Inc.
  • [F2]These stock options were canceled in exchange for a cash payment in accordance with the Agreement and Plan of Merger, dated as of May 16, 2010, among OSI Pharmaceuticals, Inc., Astellas Pharma Inc., Astellas US Holding, Inc. and Ruby Acquisition, Inc. The cash payment made with respect to each stock option equals the product of (x) the number of shares issuable upon the exercise of such option multiplied by (y) the excess, if any, of $57.50 over the exercise price per share for such option.

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT